Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Blumenstein, I. [1 ]
Xuan, S. [2 ]
Panaccione, R. [3 ]
Baert, F. [4 ]
Barreiro-de Acosta, M. [5 ]
Ye, B. D. [6 ,7 ]
Klaff, J. [2 ]
Vladea, R. [2 ]
Levy, G. [2 ]
Holweg, C. T. J. [2 ]
Gonzalez, Y. Sanchez [2 ]
Dubinsky, M. C. [8 ]
机构：
[1] Goethe Univ Clin, Frankfurt, Germany
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Calgary, Dept Gastroenterol & Hepatol, Calgary, AB, Canada
[4] AZ Delta, Dept Gastroenterol, Roeselare, Belgium
[5] Univ Hosp Santiago de Compostela, Inflammatory Bowel Dis Unit, Galicia, Spain
[6] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Gastroenterol, Seoul, South Korea
[7] Univ Ulsan, Inflammatory Bowel Dis Ctr, Seoul, South Korea
[8] Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein IBD Ctr, New York, NY USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P179
引用
收藏
页码：I333 / I334
页数：2
相关论文
共 50 条
  • [1] Benefit-Risk Assessment of Upadacitinib Treatment in Patients With Moderately to Severely Active Ulcerative Colitis
    Panaccione, Remo
    Blumenstein, Irina
    Irving, Peter
    Vladea, Ramona
    Ilo, Dapo
    Zhou, Wen
    Levy, Gweneth
    Yao, Xuan
    Dotan, Iris
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S553 - S554
  • [2] BENEFIT-RISK OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERE ULCERATIVE COLITIS (UC)
    Panaccione, Remo
    Blumenstein, Irina
    Irving, Peter
    Hedin, Charlotte
    Vladea, Ramona
    Ilo, Dapo
    Zhou, Wen
    Levy, Gweneth
    Yao, Xuan
    Dotan, Iris
    GUT, 2023, 72 (SUPPL_2) : A73 - A73
  • [3] Matching-Adjusted Indirect Comparison of Upadacitinib versus Vedolizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Vermeire, Severine
    Hedin, Charlotte
    Rubin, David T.
    Panes, Julian
    Deng, Huiwen
    Xuan, Si
    Wegrzyn, Lani
    Liu, John
    Ilo, Dapo
    Zhou, Wen
    Sanchez-Gonzalez, Yuri
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S520 - S521
  • [4] Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
    Reinisch, W.
    Panaccione, R.
    Duijvestein, M.
    Santos, D. Ceballos
    Melmed, G. Y.
    Xuan, S.
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 672 - 672
  • [5] Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison
    Reinisch, W.
    Tran, J.
    Patel, K.
    Borruel, N.
    Melmed, G. Y.
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 785 - 786
  • [6] COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB VERSUS TOFACITINIB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Reinisch, Walter
    Tran, Jacinda N.
    Patel, Kamal V.
    Borruel, Natalia
    Melmed, Gil
    Wegrzyn, Lani R.
    Levy, Gweneth
    Ilo, Dapo
    Gonzalez, Yuri Sanchez
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S650 - S651
  • [7] Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis
    Panaccione, Remo
    Danese, Silvio
    Zhou, Wen
    Klaff, Justin
    Ilo, Dapo
    Yao, Xuan
    Levy, Gweneth
    Higgins, Peter D. R.
    Loftus Jr, Edward V.
    Chen, Su
    Gonzalez, Yuri Sanchez
    Leonard, Carolyn
    Hebuterne, Xavier
    Lindsay, James O.
    Cao, Qian
    Nakase, Hiroshi
    Colombel, Jean-Frederic
    Vermeire, Severine
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (03) : 393 - 408
  • [8] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Watanabe, Mamoru
    Motoya, Satoshi
    Watanabe, Kenji
    Ogata, Haruhiko
    Kanai, Takanori
    Matsui, Toshiyuki
    Suzuki, Yasuo
    Shikamura, Mitsuhiro
    Igeta, Masataka
    Oda, Kazunori
    Hori, Tetsuharu
    Araki, Takahiro
    Hibi, Toshifumi
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S381
  • [9] Matching-adjusted indirect comparison of upadacitinib vs vedolizumab as induction therapy in patients with moderately to severely active ulcerative colitis
    Venugopal, K.
    Reinisch, W.
    Vermeire, S.
    Hedin, C.
    Rubin, D. T.
    Panes, J.
    Deng, H.
    Xuan, S.
    Wegrzyn, L.
    Liu, J.
    Ilo, D.
    Zhou, W.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 135 - 135
  • [10] Comparative efficacy and safety of upadacitinib vs tofacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
    An, Y-K
    Reinisch, W.
    Tran, J.
    Patel, K.
    Borruel, N.
    Melmed, Gy
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 128 - 129
12345